Validation of a modified substaging system (kinki criteria) for patients with intermediate-stage hepatocellular carcinoma

Oncology (Switzerland)

Volumn 89, Issue , 2015, Pages 47-52

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Iwanishi, Mina ^a   Minami, Tomohiro ^a   Chishina, Hirokazu ^a   Kono, Masashi ^a   Takita, Masahiro ^a   Kitai, Satoshi ^a   Inoue, Tatsuo ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Ida, Hiroshi ^a   Minami, Yasunori ^a   Sakurai, Toshiharu ^a   Kitano, Masayuki ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bclc stage b; Hepatocellular carcinoma; Kinki criteria; Transarterial chemoembolization

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SURVIVAL RATE; UNIVERSITY HOSPITAL; CARCINOMA, HEPATOCELLULAR; CLASSIFICATION; FOLLOW UP; LIVER FUNCTION TEST; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VALIDATION STUDY;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84965091420     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000440631     Document Type: Article

References (26)

1. International Agency for Research on Cancer: GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
2. Kudo M: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4: 39-50.
3. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
4. Kudo M: Recent advances in bioinformatics reveal the molecular heterogeneity of hepatocellular carcinoma. Liver Cancer 2014; 3: 68-70.
5. Bruix J, Sala M, Llovet JM: Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127:S179-S188.
6. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
7. Lin S, Hoffmann K, Schemmer P: Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer 2012; 1: 144-158.
8. Bruix J, Sherman M: Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
9. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
10. Kudo M, Izumi N, Kokudo N, et al: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
11. Lencioni R: Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012; 39: 503-509.
12. Minami Y, Yagyu Y, Murakami T, Kudo M: Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional conebeam CT angiography. Liver Cancer 2014; 3: 53-61.
13. Kokudo N: Recent progress in the treatment and diagnosis of hepatocellular carcinoma. Liver Cancer 2013; 2: 4.
14. Kudo M, Matsui O, Izumi N, et al: JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014; 3: 458-468.
15. Raoul JL, Gilabert M, Piana G: How to define transarterial chemoembolization failure or refractoriness: A European perspective. Liver Cancer 2014; 3: 119-124.
16. Bolondi L, Burroughs A, Dufour JF, et al: Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-359.
17. Weinmann A, Koch S, Sprinzl M, et al: Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int 2015; 35: 591-600.
18. Wang JH, Kee KM, Lin CY, et al: Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol 2015; 30: 358-363.
19. Yamakado K, Miyayama S, Hirota S, et al: Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014; 32: 260-265.
20. Yamakado K, Miyayama S, Hirota S, et al: Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jpn J Radiol 2014; 32: 644-649.
21. Mazzaferro V, Llovet JM, Miceli R, et al: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
22. Kudo M, Arizumi T, Ueshima K, et al: Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi?s subclassification (Kinki criteria). Dig Dis 2015;33:751-758.
23. Murakami T, Tsurusaki M: Hypervascular benign and malignant liver tumors that require differentiation from hepatocellular carcinoma: key points of imaging diagnosis. Liver Cancer 2014; 3: 85-96.
24. Ichikawa T, Sano K, Morisaka H: Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer 2014; 3: 97-107.
25. Kudo M: Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. Liver Cancer 2015; 4: 85-95.
26. Kudo M, Osaki Y, Matsunaga T, et al: Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis 2013; 31: 490-498.